Factors associated with treatment duration from start of second-line ramucirumab plus paclitaxel or nab-PTX for advanced gastric cancer: real-world evidence from Japanese Claim Database.

177Background: Recently, the value of RWE has been recognized to be important. We investigated the first line(1L)-2L therapy(Tx) sequence for AGC and factors associated with whole treatment period ...